A suggested approach to once-daily aminoglycoside dosing.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  1995-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/J.1365-2125.1995.TB05719.XPMID 7654477PMCID PMC1365071
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Studies on drug monitoring in thrice and once daily treatment with aminoglycosides

  2005cited by this paper
• Prediction equation estimates of creatinine clearance in the intensive care unit

  2005cited by this paper
• Aminoglycoside toxicity and relation to dose regimen.

  1994cited by this paper
• What is the Evidence for Once-Daily Aminoglycoside Therapy?

  1994cited by this paper
• Once versus thrice daily gentamicin in patients with serious infections.

  1993cited by this paper
• Practicalities of once-daily aminoglycoside dosing.

  1993cited by this paper
• Once-daily aminoglycoside dosing.

  1993cited by this paper
• Aminoglycoside cochlear ototoxicity.

  1993cited by this paper
• Mitochondrial ribosomal RNA gene mutation in a patient with sporadic aminoglycoside ototoxicity.

  1993cited by this paper
• Once-daily aminoglycoside dosing

  1993cited by this paper
• Once-daily aminoglycoside dosing.

  1993cited by this paper
• Surface action of gentamicin on Pseudomonas aeruginosa

  1993cited by this paper
• Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring.

  1993cited by this paper
• Biochemical basis of aminoglycoside ototoxicity.

  1993cited by this paper
• Once-daily aminoglycoside dosing.

  1993cited by this paper
• ANTIMICROBIAL THERAPY: Once-daily aminoglycoside dosing

  1993cited by this paper
• Once-daily aminoglycosides.

  1992cited by this paper
• Comparison of gentamicin dosing regimens using an in-vitro model.

  1992cited by this paper
• Adaptive resistance following single doses of gentamicin in a dynamic in vitro model

  1992cited by this paper
• Serum aminoglycoside clearance is predicted as poorly by renal aminoglycoside clearance as by creatinine clearance in critically ill patients

  1991cited by this paper
• Once-daily aminoglycoside therapy

  1991cited by this paper
• Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection

  1991cited by this paper
• Single daily dosing of amikacin in an in-vitro model.

  1991cited by this paper
• Efficacy of once- and thrice-daily dosing of aminoglycosides in in-vitro models of infection.

  1991cited by this paper
• Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections.

  1991cited by this paper
• Genetic aspects of antibiotic induced deafness: mitochondrial inheritance.

  1991cited by this paper
• First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use

  1991cited by this paper
• Safety, pharmacokinetics and efficacy of once-a-day netilmicin and amikacin versus their conventional schedules in patients suffering from pelvic inflammatory disease.

  1990cited by this paper
• Aminoglycoside-induced ototoxicity.

  1990cited by this paper
• Bayesian Forecasting of Serum Gentamicin Concentrations in Intensive Care Patients

  1990cited by this paper
• Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone.

  1990cited by this paper
• Failure of a nomogram to achieve target aminoglycoside concentrations.

  1990cited by this paper
• Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation.

  1990cited by this paper
• Adaptive resistance to aminoglycoside antibiotics in Pseudomonas aeruginosa.

  1989cited by this paper
• Individualised aminoglycoside dosage based on pharmacokinetic analysis is superior to dosage based on physician intuition at achieving target plasma drug concentrations.

  1989cited by this paper
• Serial pharmacokinetic dosing of aminoglycosides: a community hospital experience.

  1989cited by this paper
• Comparison of Sawchuk-Zaske and Bayesian forecasting for aminoglycosides in seriously ill patients.

  1989cited by this paper
• Determinants of efficacy and toxicity of aminoglycosides.

  1989cited by this paper
• Incidence of amikacin ototoxicity: a sigmoid function of total drug exposure independent of plasma levels.

  1989cited by this paper
• Aminoglycoside-induced hearing loss in humans

  1989cited by this paper
• Comparison of two methods for determining in vitro postantibiotic effects of three antibiotics on Escherichia coli

  1988cited by this paper
• Altered Aminoglycoside Pharmacokinetics in the Critically Ill

  1988cited by this paper
• Pharmacokinetic monitoring of nephrotoxic antibiotics in surgical intensive care patients.

  1988cited by this paper
• Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia.

  1988cited by this paper
• In vivo postantibiotic effect in a thigh infection in neutropenic mice.

  1988cited by this paper
• General mechanisms of resistance to antibiotics.

  1988cited by this paper
• Correlation between renal membrane binding and nephrotoxicity of aminoglycosides

  1987cited by this paper
• Aminoglycoside pharmacokinetics: dosage requirements and nephrotoxicity in trauma patients.

  1987cited by this paper
• Predictive Performance of Sawchuk‐Zaske and Bayesian Dosing Methods for Tobramycin

  1987cited by this paper
• Kinetics of antimicrobial activity.

  1986cited by this paper
• In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats.

  1986cited by this paper
• Variability in aminoglycoside pharmacokinetics in critically ill surgical patients

  1986cited by this paper
• Comparative Effects of Aminoglycosides on Renal Cortical and Urinary Phospholipids in the Rat

  1986cited by this paper
• Kinetics of gentamicin uptake and release in the rat. Comparison of inner ear tissues and fluids with other organs.

  1986cited by this paper
• Altered gentamicin pharmacokinetics during the perioperative period.

  1985cited by this paper
• A Bayesian feedback method of aminoglycoside dosing

  1985cited by this paper
• Comparison of Drug Dosing Methods

  1985cited by this paper
• Risk factors for nephrotoxicity in patients treated with aminoglycosides.

  1984cited by this paper
• Clinical significance of renal changes engendered by aminoglycosides in man.

  1984cited by this paper
• Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia.

  1984cited by this paper
• The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia.

  1984cited by this paper
• Multiple-Dose Non-Linear Regression Analysis Program

  1983cited by this paper
• Initial aminoglycoside levels in the critically ill.

  1983cited by this paper
• Effects of calcium and neomycin on phase behavior of phospholipid bilayers.

  1983cited by this paper
• Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin.

  1983cited by this paper
• Calcium antagonism and reversibility of gentamicin-induced loss of cochlear microphonics in the guinea pig.

  1982cited by this paper
• Gentamicin pharmacokinetics in 1,640 patients: method for control of serum concentrations

  1982cited by this paper
• Gentamicin and tobramycin kinetics

  1982cited by this paper
• Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods.

  1982cited by this paper
• Aminoglycoside Dosing in Renal Transplant Patients: Comparison of Nomogram and Individualized Pharmacokinetic Methods in Patients with Shifting Renal Function

  1982cited by this paper
• Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin.

  1980cited by this paper
• AMINOGLYCOSIDE OTOTOXICITY IN THE HUMAN

  1980cited by this paper
• Interactions of neomycin with monomolecular films of polyphosphoinositides and other lipids.

  1979cited by this paper
• Forecasting individual pharmacokinetics

  1979cited by this paper
• Comparative nephrotoxicity of aminoglycoside antibiotics in rats.

  1978cited by this paper
• Fanconi syndrome associated with cephalothin and gentamicin therapy

  1978cited by this paper
• Controlled comparison of amikacin and gentamicin.

  1977cited by this paper
• Kinetic model for gentamicin dosing with the use of individual patient parameters

  1977cited by this paper
• Clinical research on aging: strategies and directions.

  1977cited by this paper
• Nonoliguric acute renal failure.

  1977cited by this paper
• The management of fever in blood dyscrasias: results of a prospective controlled trial of a prescribing aid for gentamicin.

  1977cited by this paper
• In Vitro Comparison of Netilmicin, a Semisynthetic Derivative of Sisomicin, and Four Other Aminoglycoside Antibiotics

  1976cited by this paper
• Effect of Sodium Intake on Gentamicin Nephrotoxicity in the Rat

  1976cited by this paper
• Streptomycin Accumulation in Susceptible and Resistant Strains of Escherichia coli and Pseudomonas aeruginosa

  1976cited by this paper
• Predictability of blood levels of gentamicin in man.

  1975cited by this paper
• Gentamicin Blood Levels: a Guide to Nephrotoxicity

  1975cited by this paper
• Experience in Monitoring Gentamicin Therapy during Treatment of Serious Gram-Negative Sepsis

  1974cited by this paper
• BB-K 8, a new semisynthetic aminoglycoside antibiotic.

  1972cited by this paper
• Ototoxicity of gentamicin in man: a survey and controlled analysis of clinical experience in the United States.

  1971cited by this paper
• The dose, distribution, and excretion of gentamicin with speical reference to renal failure.

  1969cited by this paper
• Nebramycin, a new broad-spectrum antibiotic complex. II. Description of Streptomyces tenebrarius.

  1967cited by this paper
• GENTAMICIN, A NEW ANTIBIOTIC COMPLEX FROM MICROMONOSPORA.

  1963cited by this paper
• Production and isolation of a new antibiotic: kanamycin.

  1957cited by this paper
• Neomycin, a New Antibiotic Active against Streptomycin-Resistant Bacteria, including Tuberculosis Organisms.

  1949cited by this paper

• Acquired Bacterial Resistance to Antibiotics and Resistance Genes: From Past to Future

  2025cites this paper
• Microphysiological Glomerular Filtration Barriers: Current Insights, Innovations, and Future Applications

  2025cites this paper
• Aminoglycosides: an update on indications, dosing and monitoring

  2025cites this paper
• Sampling from covariate distribution may not always be necessary in PK/PD simulations: illustrative examples with antibiotics

  2025influential citation
• Three methods to optimise polymyxin B dosing using estimated AUC after first dose: validation with the data generated by Monte Carlo simulation

  2024cites this paper
• Comparative assessment of trough and peak levels and AUC24 for amikacin in nontuberculous mycobacterial infection.

  2024cites this paper
• A simple HPLC–MS/MS method for the determination of polymyxin B in human plasma and its application in the pharmacokinetic study in elderly patients infected with multidrug-resistant Gram-negative bacteria

  2024cites this paper
• Ribosomal a site binding pattern differs between arm methyltransferases from clinical pathogens and a natural producer of aminoglycosides.

  2024cites this paper
• Comprehensive guidance for antibiotic dosing in obese adults: 2022 update

  2023cites this paper
• Review of Tobramycin Dosing in Pediatric Patients With Cystic Fibrosis.

  2023cites this paper
• Chinese consensus guidelines for therapeutic drug monitoring of polymyxin B, endorsed by the Infection and Chemotherapy Committee of the Shanghai Medical Association and the Therapeutic Drug Monitoring Committee of the Chinese Pharmacological Society

  2023cites this paper
• Augmented Renal Clearance in Severe Infections—An Important Consideration in Vancomycin Dosing: A Narrative Review

  2022cites this paper
• Can intracellular Staphylococcus aureus in osteomyelitis be treated using current antibiotics? A systematic review and narrative synthesis

  2022cites this paper
• Is there a multinational consensus of tobramycin prescribing and monitoring for cystic fibrosis? Survey of current therapeutic drug monitoring practices in USA/Canada, UK/Ireland, and Australia/New Zealand

  2022cites this paper
• Gentamicin Administration in Dialysis Patients: Before or After Hemodialysis?

  2022cites this paper
• Bayesian Forecasting for Intravenous Tobramycin Dosing in Adults With Cystic Fibrosis Using One Versus Two Serum Concentrations in a Dosing Interval

  2021cites this paper
• Therapeutic Drug Monitoring of Antibiotics: Defining the Therapeutic Range

  2021cites this paper
• Pharmacokinetic/pharmacodynamic evaluation of tobramycin dosing in critically ill patients: the Hartford nomogram does not fit.

  2021cites this paper
• Precision Drug Delivery for Vancomycin Efficacy and Safety in Critically Ill Patients

  2021cites this paper
• Resistance Patterns from Urine Cultures in Children Aged 0 to 6 Years: Implications for Empirical Antibiotic Choice

  2021cites this paper
• Evaluating the Impact of Education on Pharmacist Tobramycin Dose Recommendations for Cystic Fibrosis and a Review of Perceptions on Pharmacist-Led Charting

  2021cites this paper
• Appropriate Use of Glycopeptide Antibiotics and Therapeutic Drug Monitoring for Invasive Infections

  2021cites this paper
• Therapeutic Drug Monitoring of Antibiotic Drugs in Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis: A Critical Review

  2021cites this paper
• Aminoglycoside dosing and monitoring for Pseudomonas aeruginosa during acute pulmonary exacerbations in cystic fibrosis

  2021cites this paper
• Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Socie

  2020cites this paper
• Evaluation of amikacin use and comparison of the models implemented in two Bayesian forecasting software packages to guide dosing

  2020cites this paper
• Aminoglycosides in critically ill patients: which dosing regimens for which pathogens?

  2020cites this paper
• Some Suggestions from PK/PD Principles to Contain Resistance in the Clinical Setting—Focus on ICU Patients and Gram-Negative Strains

  2020cites this paper
• First‐Dose Vancomycin Pharmacokinetics Versus Empiric Dosing on Area‐Under‐the‐Curve Target Attainment in Critically Ill Patients

  2020cites this paper
• Caspofungin PK in critically ill patients after the first and fourth doses: suggestions for therapeutic drug monitoring?

  2020cites this paper
• Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#

  2020cites this paper
• Safety and Outcomes of Linezolid Use for Nocardiosis

  2020cites this paper
• Biodegradation of antibiotics: the new resistance determinants - part I.

  2020cites this paper
• The evaluation of the appropriate gentamicin use for preterm infants

  2019cites this paper
• Development of a Novel Pharmaceutical Formula of Nanoparticle Lipid Carriers of Gentamicin/α-Tocopherol and In Vivo Assessment of the Antioxidant Protective Effect of α-Tocopherol in Gentamicin-Induced Nephrotoxicity

  2019cites this paper
• PHARMACOKINETIC-PHARMACODYNAMIC ANALYSIS OF WEIGHT AND 1 HEIGHT SCALED TOBRAMYCIN DOSAGE REGIMENS FOR PATIENTS WITH 2 CYSTIC FIBROSIS

  2019cites this paper
• Individualization of Treatment with Gentamicin in Neonates Based on Drug Concentration in The Blood Serum

  2019cites this paper
• Evaluation of Amikacin Pharmacokinetics in Critically Ill Patients with Intra-abdominal Sepsis

  2019cites this paper
• Microbial Products and Biotechnological Applications Thereof: Proteins, Enzymes, Secondary Metabolites, and Valuable Chemicals

  2019cites this paper
• Use of a fluorescence assay to determine relative affinities of semisynthetic aminoglycosides to small RNAs representing bacterial and mitochondrial A sites.

  2019cites this paper
• Therapeutic monitoring of vancomycin: A revised consensus guideline and review

  2019cites this paper
• Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX‐02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers

  2019cites this paper
• Antibiotic Consideration in Transplant Recipients

  2019cites this paper
• Potential Association of Weight-Based Gentamicin with Increased Acute Kidney Injury in Urologic Prosthetic Surgery.

  2019cites this paper
• Optimising antimicrobial therapy through the use of Bayesian dosing programs

  2019cites this paper
• Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials

  2019cites this paper
• Pharmacokinetic/pharmacodynamic analysis of weight- and height-scaled tobramycin dosage regimens for patients with cystic fibrosis.

  2019cites this paper
• Gentamicin as Empirical Treatment in Hemodialysis Patients: Safety, Pharmacokinetics, and Pharmacodynamics

  2019cites this paper
• Ready for TDM: Simultaneous quantification of amikacin, vancomycin and creatinine in human plasma employing ultra-performance liquid chromatography-tandem mass spectrometry.

  2019cites this paper
• Milk thistle (Silybum Marianum) as an antidote or a protective agent against natural or chemical toxicities: a review

  2018cites this paper
• A label-free fluorescent aptasensor for detection of kanamycin based on dsDNA-capped mesoporous silica nanoparticles and Rhodamine B.

  2018cites this paper
• Efficacy of selective digestive decontamination in patients with multiple myeloma undergoing high-dose chemotherapy and autologous stem cell transplantation

  2018cites this paper
• Inhalational Gentamicin Treatment Is Effective Against Pneumonic Plague in a Mouse Model

  2018cites this paper
• Topical application of aminoglycoside antibiotics enhances host resistance to viral infections in a microbiota-independent manner

  2018cites this paper
• Monitoring of gentamicin serum concentrations in obstetrics and gynaecology patients in Namibia

  2018cites this paper
• Monitoring of Tobramycin Exposure: What is the Best Estimation Method and Sampling Time for Clinical Practice?

  2018cites this paper
• Optimizing Vancomycin Monitoring in Pediatric Patients

  2018cites this paper
• The effect of PTC124 on choroideremia fibroblasts and iPSC-derived RPE raises considerations for therapy

  2018cites this paper
• Microbiota-independent antiviral protection conferred by aminoglycoside antibiotics

  2018cites this paper
• Anaerobic radical enzymes for biotechnology

  2018cites this paper
• External Evaluation of a Gentamicin Infant Population Pharmacokinetic Model Using Data from a National Electronic Health Record Database

  2018cites this paper
• Evaluation of Tobramycin Exposure Predictions in Three Bayesian Forecasting Programmes Compared with Current Clinical Practice in Children and Adults with Cystic Fibrosis

  2018cites this paper
• Pharmacokinetics of a Once Daily Dosing Regimen of Gentamicin in a Patient with Delayed Wound Healing

  2018cites this paper
• Therapeutic Drug Monitoring: More Than Avoiding Toxicity

  2018cites this paper
• The practice of once-daily aminoglycoside dosing in Canada: A national survey

  2018cites this paper
• Extended Interval Tobramycin Pharmacokinetics in a Pediatric Patient With Primary Ciliary Dyskinesia Presenting With an Acute Respiratory Exacerbation.

  2018cites this paper
• Pharmacokinetics of intravenous and nebulized gentamicin in critically ill patients

  2018cites this paper
• Clearance of intracellular Klebsiella pneumoniae infection using gentamicin‐loaded nanoparticles

  2018cites this paper
• Postpartum infective endocarditis with Enterococcus faecalis in Japan: a case report

  2017cites this paper
• Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies

  2017cites this paper
• Effects of pre and post‐treatments with dipyridamole in gentamicin‐induced acute nephrotoxicity in the rat

  2017cites this paper
• QSAR based therapeutic management of M. tuberculosis

  2017cites this paper
• Estimating drug‐free period using a graphical method: an alternative way to monitor extended‐interval dosing of gentamicin therapy

  2017cites this paper
• Empirical gentamicin dosing based on serum creatinine levels in premature and term neonates.

  2017cites this paper
• Dosing antibiotics in neonates: review of the pharmacokinetic data.

  2017cites this paper
• The Effect of Alpha-Lipoic Acid on Preventing Amikacin-Induced DNA Damage in Rats

  2017cites this paper
• Development and validation of a sensitive LC–MS/MS method without derivatization/ion‐pairing agents for etimicin quantification in rat plasma, internal ear and kidney

  2017cites this paper
• Genetic basis of persister formation in Escherichia coli

  2017cites this paper
• Disability Levels and Cognitive Functioning Reported by Patients Impaired by Gentamicin and Other Aminoglycosides

  2017cites this paper
• Non-coding RNAs as antibiotic targets.

  2017cites this paper
• Multidrug Resistant Pseudomonas Mycotic Pseudoaneurysm following Cardiac Transplant Bridged by Ventricular Assistant Device

  2017cites this paper
• Aminoglycoside antibiotics perturb physiologically important microRNA contributing to drug toxicity

  2017cites this paper
• Therapeutic drug monitoring of anti-infective agents in critically ill patients

  2016cites this paper
• d-Methionine reduces tobramycin-induced ototoxicity without antimicrobial interference in animal models.

  2016cites this paper
• Gentamicin Pharmacokinetics and Monitoring in Pediatric Febrile Neutropenic Patients.

  2016cites this paper
• Synthesis, spectroscopy, structures and antimicrobial activity of mixed-ligand zinc(II) complexes of 5-nitro-salicylaldehyde thiosemicarbazones

  2016cites this paper
• Multi-drug resistant tuberculosis in the Netherlands

  2016cites this paper
• D-methionine (D-met) significantly reduces kanamycin-induced ototoxicity in pigmented guinea pigs

  2016cites this paper
• Single Daily Dose of Aminoglycosides in comparison with Multiple Daily Dose in Iraq

  2016cites this paper
• Aminoglycoside-induced nephrotoxicity in children

  2016cites this paper
• Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis

  2016cites this paper
• ALOE VERA ATTENUATES GENTAMICIN-INDUCED NEPHROTOXICITY IN WISTAR ALBINO RATS: HISTOPATHOLOGICAL AND BIOCHEMICAL CHANGES

  2016cites this paper
• Melatonin synergistically enhances protective effect of atorvastatin against gentamicin-induced nephrotoxicity in rat kidney.

  2016cites this paper
• Extended-interval gentamicin administration in neonates: a simplified approach

  2016cites this paper
• Pharmacokinetics I: PK-PD Approach, the Case of Antibiotic Drug Development

  2016influential citation
• Gentamicin dosing strategy in patients with end-stage renal disease receiving haemodialysis: evaluation using a semi-mechanistic pharmacokinetic/pharmacodynamic model.

  2016cites this paper
• Synthesis and structures of 5-methoxy-salicylaldehyde thiosemicarbazonates of copper(II): Molecular spectroscopy, ESI-mass studies and antimicrobial activity

  2016cites this paper
• Therapeutic monitoring of amikacin and gentamicin in critically and noncritically ill patients

  2016cites this paper
• Pharmacokinetics of once and twice daily dosing of intravenous tobramycin in paediatric patients with cystic fibrosis

  2016cites this paper
• Effective in Vitro Synergy of Piperacillin/Tazobactam Plus either Netilmicin or Aztreonam against Metallo-β-lactamase-producing Pseudomonas Aeruginosa

  2016cites this paper